US 12,605,433 B2Granted

Antibody specifically binding to PTK7 and use thereof

AssigneesUIF (University Industry Foundation), Yonsei University, Osong Medical Innovation Foundation

InventorsSeung Taek Lee, Won Sik Shin, Si Won Oh, So Young Choi, Se Ra Lee, So Ra Park

Life of this patent

Estimating the term…

Loading patent…

Abstract

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

An anti-PTK7 antibody or a functional fragment thereof, the anti-PTK7 antibody or the functional fragment thereof specifically binding to protein tyrosine kinase 7 (PTK7) and comprising a heavy-chain variable region (HCVR) and a light-chain variable region (LCVR) selected from the group consisting of:

(i) a HCVR comprising a CDR1-VH having the amino acid sequence as set forth in SEQ ID NO:
1, a CDR2-VH having the amino acid sequence set forth in SEQ ID NO:
2, a CDR3-VH having the amino acid sequence set forth in SEQ ID NO:
3, and a LCVR comprising a CDR1-VL having the amino acid sequence as set forth in SEQ ID NO:
4, a CDR2-VL having the amino acid sequence set forth in SEQ ID NO:
5, a CDR3-VL having the amino acid sequence set forth in SEQ ID NO:
6;
(ii) a HCVR comprising a CDR1-VH having the amino acid sequence as set forth in SEQ ID NO:
7, a CDR2-VH having the amino acid sequence set forth in SEQ ID NO:
8, a CDR3-VH having the amino acid sequence set forth in SEQ ID NO:
9, and a LCVR comprising a CDR1-VL having the amino acid sequence as set forth in SEQ ID NO:
10, a CDR2-VL having the amino acid sequence set forth in SEQ ID NO:
11, a CDR3-VL having the amino acid sequence set forth in SEQ ID NO:
12;
(iii) a HCVR comprising a CDR1-VH having the amino acid sequence as set forth in SEQ ID NO:
13, a CDR2-VH having the amino acid sequence set forth in SEQ ID NO:
14, a CDR3-VH having the amino acid sequence set forth in SEQ ID NO:
15, and a LCVR comprising a CDR1-VL having the amino acid sequence as set forth in SEQ ID NO:
16, a CDR2-VL having the amino acid sequence set forth in SEQ ID NO:
17, a CDR3-VL having the amino acid sequence set forth in SEQ ID NO:
18;
and
(iv) a HCVR comprising a CDR1-VH having the amino acid sequence as set forth in SEQ ID NO:
19, a CDR2-VH having the amino acid sequence set forth in SEQ ID NO:
20, a CDR3-VH having the amino acid sequence set forth in SEQ ID NO:
21, and a LCVR comprising a CDR1-VL having the amino acid sequence as set forth in SEQ ID NO:
22, a CDR2-VL having the amino acid sequence set forth in SEQ ID NO:
23, a CDR3-VL having the amino acid sequence set forth in SEQ ID NO:
24.

26 more elements

Abstract

Claims16